Results 41 to 50 of about 1,973 (199)
Is Alopecia a Clinical Symptom in Kawasaki Disease? [PDF]
Journal of Kerman University of Medical Sciences, 2014 A 20-months-old infant was admitted with prolonged fever, bilateral non-purulent conjunctivitis, strawberry tongue, lip cracking and maculopapular rash. Left branch coronary aneurysm formation was detected in Color-Doppler echocardiography. The diagnosis
Mohammad Mehdi Bagheri +3 more
doaj
A patient with rickets and alopecia totalis
Journal of Clinical and Scientific Research, 2023 Abstract Rickets is a disorder of bone mineralisation. Common causes of rickets are dietary calcium and Vitamin deficiency. Mutations in vitamin D activity are known to cause Vitamin D-resistant rickets (VDRRs). Various types of VDRRs have been identified – type I and type II along with their subtypes.
Shanthisree Edara +5 more
openaire +1 more source
Dermatology and Therapy, 2020 Introduction Cyclosporine is commonly used in treatment for alopecia areata. It can be administered as a monotherapy or in combination with systemic corticosteroids, with various outcomes.
Joanna Nowaczyk +4 more
doaj +1 more source
PUVA treatment of alopecia totalis
Acta Dermato-Venereologica, 1983 40 patients with alopecia totalis have been treated with PUVA. 26 did not respond, 6 experienced a partial hair regrowth, while 8 got a complete regrowth. However, relapses were frequent, occurring at an early stage.
O, Larkö, G, Swanbeck
openaire +2 more sources
Interleukin-15 and Tumor Necrosis Factor-α in Iraqi Patients with Alopecia Areata
Dermatology Research and Practice, 2023 Background. Alopecia areata (AA) is a common form of noncicatricial hair loss of unknown cause, affecting 0.1-0.2% of the general population. Most evidence supports the hypothesis that it is disease of the hair follicle of autoimmune nature mediated by T-
Zainab A. Kamil +2 more
doaj +1 more source
Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Frontiers in Medicine, 2023 Alopecia areata (AA) is a non-scarring hair loss disorder. Alopecia totalis (AT) and alopecia universalis (AU) are the severe subtypes of AA. Age of onset before 6 years of age, disease duration of more than 1 year, and extensive alopecia involving more ...
Lu Cai +7 more
doaj +1 more source
Alopecia totalis and universalis long‐term outcomes: a review [PDF]
, 2020 Alopecia totalis (AT) and universalis (AU) represent the most severe subtypes of alopecia areata with more dramatic features and worse prognosis. The goal of this review is to identify all studies with long‐term prognostic data on patients with AT and AU
A. Tosti +5 more
core +1 more source
Journal of Dermatology and Dermatologic Surgery, 2021 Janus kinase (JAK) inhibitors have been identified as an effective treatment option for severe alopecia areata (AA), but response is variable among patients.
Erinolaoluwa F Araoye, Crystal Aguh
doaj +1 more source
The Genetic Basis of Alopecia Areata: HLA Associations with Patchy Alopecia Areata Versus Alopecia Totalis and Alopecia Universalis [PDF]
, 1999 Many diseases, notably those having a strong autoimmune component, have been shown to have an association with specific human leukocyte antigens (HLA).
Lou, Calvin D. +2 more
core +1 more source
Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
Vaccines, 2022 Limited data concerning the development of autoimmune skin diseases after COVID-19 vaccination are currently available. Recently, a few reports described the development, worsening or recurrence of alopecia areata after the administration of COVID-19 ...
Francesco Tassone +5 more
doaj +1 more source